Biomedica — the leading AI disease screening brand in the Asia-Pacific empowers osteoporosis and cancer screening, providing precise protection for the health of women, the elderly, and cancer patients.

With a core philosophy of “simple and precise,” Biomedica debuted two key solutions at the 2024 Taiwan Healthcare+ Expo: its AI-powered osteoporosis screening system and the smart NGS precision medical laboratory. Dedicated to advancing women’s health and smart healthcare, Biomedica exhibited at booths hosted by Intel, the Southern Taiwan Science Park, and the Department of Industrial Technology (DOIT), showcasing its broad technology applications. A physical machine demo and AI use cases were featured at the Intel booth, integrating with the high-performance HPE ProLiant DL Gen11 series server to further enhance system stability and computing power.

Biomedica CEO Han-Wei Chang stated:
“Preventive medicine and population health management are the keys to a healthier Taiwan. Our AI-powered osteoporosis screening and smart NGS lab solutions improve both screening efficiency and diagnostic accuracy, enabling earlier disease detection and precision treatment to provide more effective healthcare services.”

Breaking Through the Bottleneck in Osteoporosis Screening: Faster Detection with AI

As Taiwan enters a super-aged society, osteoporosis has become a major health concern for women, increasing risks of fractures and declining quality of life. Biomedica’s AI imaging analysis system not only boosts screening efficiency but also supports healthy aging and women's health management, contributing to a comprehensive preventive care ecosystem. The system enhances standard X-ray machines with AI-enabled components, including the X-ray detector, AI-powered PC, X1 Pro medical imaging workstation, and an osteoporosis screening kit. By leveraging existing X-ray devices combined with Intel-based AI PCs and Intel OpenVINO technology, a professional bone density report can be generated in just six seconds.

A study published by the Taiwanese Osteoporosis Association confirmed that Biomedica’s X1AI-Osteo module demonstrated high accuracy and strong correlation with the gold standard DXA results (R=0.996)¹, earning high recognition from clinical experts. With three core features—precision, compatibility with existing workflows, and fast reporting—the solution meets the growing demand for efficient and accurate screening. It is now distributed and certified across 11 Asia-Pacific countries, adopted by over 150 medical institutions, and has positioned Biomedica as a leading osteoporosis diagnostic brand in the region. The solution significantly streamlines and accelerates diagnostic processes, promoting a new era of high-quality healthcare services.

Smart NGS Lab for Cancer Screening: Advancing Precision Medicine

Biomedica’s smart NGS precision medical laboratory system is designed for genetic screening of major diseases such as cancer. It offers high efficiency and low error rates in gene testing. The system integrates multiple automated components and is the first to leverage large language models (LLMs) to simplify sample preparation, enhance lab personnel efficiency, and improve testing accuracy. Its modular design allows seamless integration into existing lab workflows, enabling healthcare professionals to easily collaborate with the LLM to complete sample processing, data analysis, and report generation. The result is a stable and scalable genetic testing workflow for cancer screening.

This solution is jointly developed by Biomedica, Foxlink, and biotech company Illumina, successfully integrating equipment to automate the gene sequencing process. It delivers a comprehensive precision medicine solution, showcasing the future of smart diagnostics.